AOD-9604 in Celica — Fat Loss Peptide Research Guide
AOD-9604 research guide for Celica. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Unlike everyday supplements stocked in every health store, AOD-9604 is distributed via a specialist research supply market that Celica residents reach through online vendors. The benefit of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers access to better quality signals than local retail ever could. What consistently distinguishes top AOD-9604 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety screening. What follows is a vendor evaluation and quality guide built specifically around AOD-9604, covering everything a Celica researcher needs before placing a first order.
What Studies Say About AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Celica comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Where to Buy AOD-9604 — A Researcher's Guide
The most reliable path to quality AOD-9604 is engaging research communities before vendor sites — peptide forums aggregate real purchasing experience that are more trustworthy than marketing materials. When reviewing a AOD-9604 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. Positive vendor signals beyond COA quality: established track record of at least two years, responsive technical support who understand testing methodology, and temperature-appropriate packaging with desiccant. For Celica researchers making a first AOD-9604 purchase: apply these quality criteria before ordering, order conservatively at first, and verify batch traceability on arrival before use.
Order AOD-9604 — ships to Celica
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and restricted human research data. Storage requirements for AOD-9604: lyophilised powder at −20°C, reconstituted solution kept at 2-8°C refrigerated and consumed within 4 weeks; reconstitute only with bac water. The primary quality-related safety risk in AOD-9604 research is endotoxin contamination from poor sourcing — a documented endotoxin result in your specific batch certificate is the specific protection against this risk. PubMed and related preprint servers are the primary literature resources for AOD-9604 research; focus on peer-reviewed publications with documented compound quality over conference abstracts or single case observations.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
